BioWorld

June 18, 2007

Lpath Moving Sphingomab Into Clinic With $16.8M Financing

Lpath Inc. closed the second tranche of an April private placement, for a total financing of $16.8 million to push its lead compound, the anti-angiogenic compound Sphingomab, into the clinic.(BioWorld Today) Read More

TransOral Reports Positive Data From Phase III Trial In Insomnia

Analyst Opinion Divided On La Jolla's Riquent For Lupus

NewCo News: Tempo Hurries To Target Nanoparticle Combo Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...